Risk reduction strategies in ischaemic stroke: The role of antiplatelet therapy

Clinical Drug Investigation

Volumn 24, Issue 5, 2004, Pages 245-254

  Alberts, Mark J ^a   Atkinson, Richard ^b  

^a NORTHWESTERN UNIVERSITY   (United States)

^b Sutter Medical Center   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ANTILIPEMIC AGENT; ANTITHROMBOCYTIC AGENT; CLOPIDOGREL; CYCLOOXYGENASE 2 INHIBITOR; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIPYRIDAMOLE; HEPARIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; IBUPROFEN; INDAPAMIDE; NONSTEROID ANTIINFLAMMATORY AGENT; PERINDOPRIL; RAMIPRIL; SIMVASTATIN; TELMISARTAN; TICLOPIDINE; WARFARIN;

ACUTE HEART INFARCTION; ANGIOPLASTY; ANTICOAGULANT THERAPY; ARTERY THROMBOSIS; BRAIN ISCHEMIA; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CAROTID ARTERY OBSTRUCTION; CAROTID ENDARTERECTOMY; CEREBROVASCULAR ACCIDENT; CLINICAL FEATURE; CLINICAL TRIAL; CORONARY ARTERY DISEASE; CORONARY STENT; DIABETES MELLITUS; DIARRHEA; DIGESTIVE SYSTEM FUNCTION DISORDER; DRUG SAFETY; DYSLIPIDEMIA; EMBOLISM; FEVER; GASTROINTESTINAL DISEASE; GASTROINTESTINAL HEMORRHAGE; HEADACHE; HEART ATRIUM FIBRILLATION; HEART INFARCTION; HEART LEFT VENTRICLE HYPERTROPHY; HEMOLYTIC ANEMIA; HOMOCYSTINURIA; HUMAN; HYPERCHOLESTEROLEMIA; HYPERTENSION; IMMOBILIZATION; KIDNEY DISEASE; LIFESTYLE; LONG TERM CARE; LOW FAT DIET; MITRAL VALVE STENOSIS; NEUROLOGIC DISEASE; NEUTROPENIA; OBESITY; PRIMARY PREVENTION; PRIORITY JOURNAL; RASH; RECURRENT DISEASE; REVIEW; RISK FACTOR; RISK REDUCTION; SECONDARY PREVENTION; SMOKING; SMOKING CESSATION; THROMBOCYTE; THROMBOCYTOPENIA; THROMBOGENESIS; THROMBOTIC THROMBOCYTOPENIC PURPURA; TRANSIENT ISCHEMIC ATTACK; VASCULAR DISEASE;

EID: 2542485711     PISSN: 11732563     EISSN: None     Source Type: Journal    
DOI: 10.2165/00044011-200424050-00001     Document Type: Review

References (56)

1. Mohr JP, Albers GW, Amarenco P, et al. Etiology of stroke. Stroke 1997; 28: 1501-6
2. Lammie GA. Hypertensive cerebral small vessel disease and stroke. Brain Pathol 2002; 12: 358-70
3. De Jong G, Kessels F, Lodder J. Two types of lacunar infarcts: further arguments from a study on prognosis. Stroke 2002; 33: 2072-6
4. Albers GW, Caplan LR, Easton JD, et al. Transient ischemic attack: proposal for a new definition. N Engl J Med 2002; 347: 1713-6
5. Johnston SC, Gress DR, Browner WS, et al. Short-term prognosis after emergency department diagnosis of TIA. JAMA 2000; 284: 2901-6
6. Hankey GJ. Long-term outcome after ischaemic stroke/transient ischaemic attack. Cerebrovasc Dis 2003; 16 Suppl. 1: 14-9
7. Droste DW, Ringelstein EB. Evaluation of progression and spread of atherothrombosis. Cerebrovasc Dis 2002; 13 Suppl. 1: 7-11
8. Sacco RL, Shi T, Zamanillo MC, et al. Predictors of mortality and recurrence after hospitalized cerebral infarction in an urban community: the Northern Manhattan Stroke Study. Neurology 1994; 44: 626-34
9. Hardie K, Hankey GJ, Jamrozik K, et al. Ten-year survival after first-ever stroke in the Perth Community Stroke Study. Stroke 2003; 34: 1842-6
10. Bauters C. Atherothrombosis: the same process for different arterial territories? Ann Cardiol Angeiol (Paris) 2002; 51: 177-80
11. Yuan C, Zhang SX, Polissar NL, et al. Identification of fibrous cap rupture with magnetic resonance imaging is highly associated with recent transient ischemic attack or stroke. Circulation 2002; 105: 181-5
12. Carr S, Farb A, Pearce WH, et al. Atherosclerotic plaque rupture in symptomatic carotid artery stenosis. J Vasc Surg 1996; 23: 755-65
13. Corti R, Badimon JJ. Biologic aspects of vulnerable plaque. Curr Opin Cardiol 2002; 17: 616-25
14. Harker LA. Therapeutic inhibition of platelet function in stroke. Cerebrovasc Dis 1998; 8 Suppl. 5: 8-18
15. Marquardt L, Ruf A, Mansmann U, et al. Course of platelet activation markers after ischemic stroke. Stroke 2002; 33: 2570-4
16. Di Napoli M, Papa F, the Villa Pini Stroke Data Bank Investigators. Inflammation, hemostatic markers, and antithrombotic agents in relation to long-term risk of new cardiovascular events in first-ever ischemic stroke patients. Stroke 2002; 33: 1763-71
17. Blann AD, Landray MJ, Lip GY. ABC of antithrombotic therapy: an overview of antithrombotic therapy. BMJ 2002; 325: 762-5
18. UK-TIA Study Group. The United Kingdom transient ischaemic attack (UK-TIA) aspirin trial: final results. J Neurol Neurosurg Psychiatry 1991; 54: 1044-54
19. Lai SM, Alter M, Friday G, et al. A multifactorial analysis of risk factors for recurrence of ischemic stroke. Stroke 1994; 25: 958-62
20. Collins R, MacMahon S. Blood pressure, antihypertensive drug treatment and the risks of stroke and coronary artery disease. Br Med Bull 1994; 50: 272-98
21. Leys D, Deplanque D, Mounier-Vehier C, et al. Stroke prevention: management of modifiable vascular risk factors. J Neurol 2002; 249: 507-17
22. Ginsberg HN. Treatment for patients with the metabolic syndrome. Am J Cardiol 2003; 91 (7A): 29-39E
23. Straus SE, Majumdar SR, McAlister FA. New evidence for stroke prevention: scientific review. JAMA 2002; 288: 1388-95
24. Hart RG, Halperin JL, McBride R, et al. Aspirin for the primary prevention of stroke and other major vascular events. Arch Neurol 2000; 57: 326-32
25. Steering Committee of the Physicians' Health Study Research Group. Final report on the aspirin component of the ongoing Physicians' Health Study. N Engl J Med 1989; 321: 129-35
26. Eidelman RS, Hebert PR, Weisman SM, et al. An update on aspirin in the primary prevention of cardiovascular disease. Arch Intern Med 2003; 163: 2006-10
27. Byington RP, Davis BR, Plehn JF, et al. Reduction of stroke event with pravastatin: the Prospective Pravastatin Pooling (PPP) project. Circulation 2001; 103: 387-92
28. Waters DD, Schwartz GG, Olsson AG, et al. Effects of atorvastatin on stroke in patients with unstable angina or non-Q-wave myocardial infarction: a Myocardial Ischemia Reduction with Aggressive Cholesterol Lowering (MIRACL) substudy. Circulation 2002; 106: 1690-5
29. Heart Protection Study Collaborative Group. Effects of cholesterol-lowering with simvastatin on stroke and other major vascular events in 20536 people with cerebrovascular disease or other high-risk conditions. Lancet 2004; 363: 757-67
30. Expert Panel on Detection, Evaluation and Treatment of High Blood Cholesterol in Adults. Executive summary of the third report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). JAMA 2001; 285: 2486-97
31. Heart Protection Study Collaborative Group. MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial. Lancet 2002; 360: 7-22
32. Heart Outcomes Prevention Evaluation Study Investigators. Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. N Engl J Med 2002; 342: 145-53
33. Sleight P, Yusuf S, Pogue J, et al. Blood pressure reduction and cardiovascular risk in HOPE study. Lancet 2001; 358: 2130-1
34. Progress Collaborative Group. Randomised trial of a perindopril-based blood-pressure-lowering regimen among 6,105 individuals with previous stroke or transient ischaemic attack. Lancet 2001; 358: 1033-41
35. Coull BM, Williams LS, Goldstein LB, et al. Anticoagulants and antiplatelet agents in acute ischemic stroke: report of the Joint Stroke Guideline Development Committee of the American Academy of Neurology and the American Stroke Association. Stroke 2002; 33: 1934-42
36. Antithrombotic Trialists' Collaboration. Collaborative metaanalysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients. BMJ 2002; 324: 71-86
37. Grundmann K, Jaschonek K, Kleine B, et al. Aspirin non-responder status in patients with recurrent cerebral ischemic attacks. J Neurol 2003; 250: 63-6
38. Gum PA, Kottke-Marchant K, Welsh PA, et al. A prospective, blinded determination of the natural history of aspirin resistance among stable patients with cardiovascular disease. J Am Coll Cardiol 2003; 41: 961-5
39. Alberts MJ, Bergman DL, Molner E, et al. Antiplatelet effect of aspirin in patients with cerebrovascular disease. Stroke 2004; 35: 175-8
40. Valles J, Santos MT, Aznar J, et al. Erythrocyte promotion of platelet reactivity decreases the effectiveness of aspirin as an antithrombotic therapeutic modality: the effect of low-dose aspirin is less than optimal in patients with vascular disease due to prothrombotic effects of erythrocytes on platelet reactivity. Circulation 1998; 97: 350-5
41. Catella-Lawson F, Reilly MP, Kapoor SC, et al. Cyclo-oxygenase inhibitors and the antiplatelet effects of aspirin. N Engl J Med 2001; 345: 1809-17
42. MacDonald TM, Wei L. Effect of ibuprofen on cardioprotective effect of aspirin. Lancet 2003; 361: 573-4
43. Howes LG, Krum H. Selective cyclo-oxygenase-2 inhibitors and myocardial infarction: how strong is the link? Drug Saf 2002; 25: 829-35
44. Hankey GJ, Sudlow CLM, Dunbabin PW. Thienopyridines or aspirin to prevent stroke and other serious vascular events in patients at high risk of vascular disease? A systematic review of the evidence from randomized trials. Stroke 2000; 31: 1779-84
45. CAPRIE Steering Committee. A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). Lancet 1996; 348: 1329-39
46. Hacke W. From CURE to MATCH: ADP receptor antagonists as the treatment of choice for high-risk atherothrombotic patients. Cerebrovasc Dis 2002; 13 Suppl. 1: 22-6
47. CURE Investigators. Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation. N Engl J Med 2001; 345: 494-502
48. Steinhubl SR, Berger PB, Mann JT, et al. Early and sustained dual oral antiplatelet therapy following percutaneous coronary intervention: a randomized controlled trial. JAMA 2002; 288: 2411-20
49. Diener HC, Cunha L, Forbes C, et al. European Stroke Prevention Study 2: dipyridamole and acetylsalicylic acid in the secondary prevention of stroke. J Neurol Sci 1996; 143: 1-13
50. Ticlopidine Aspirin Stroke Study Group. A randomized trial comparing ticlopidine hydrochloride with aspirin for the prevention of stroke in high-risk patients. N Engl J Med 1989; 321: 501-7
51. Gorelick PB, Richardson D, Kelly M, et al. Aspirin and ticlopidine for prevention of recurrent stroke in Black patients: a randomized trial. JAMA 2003; 289: 3005-7
52. He J, Whelton PK, Vu B, et al. Aspirin and risk of hemorrhagic stroke: a meta-analysis of randomized controlled trials. JAMA 1998; 280: 1930-5
53. Serebruany VL, Malinin AI, Eisert RM, et al. Risk of bleeding complications with antiplatelet agents: meta-analysis of 338,191 patients enrolled in 50 randomized controlled trials. Am J Hematol 2004; 75: 40-7
54. Derry S, Loke YK. Risk of gastrointestinal haemorrhage with long term use of aspirin: meta-analysis. BMJ 2000; 321: 1183-7
55. Zakarija A, Bandarenko N, Pandey DK, et al. Clopidogrel-associated TTP: an update of pharmacovigilance efforts conducted by independent researchers, pharmaceutical suppliers, and the Food and Drug Administration. Stroke 2004; 35: 533-7
56. Albers GW, Amarenco P, Easton JD, et al. Antithrombotic and thrombolytic therapy for ischemic stroke. Chest 2001; 119 (1 Suppl.): 300S-20S